Related Experiment Videos
Clopidogrel After Coronary Stenting.
1Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Current Interventional Cardiology Reports
|November 30, 2000
Summary
Clopidogrel is a safer and faster-acting alternative to ticlopidine for preventing stent thrombosis after stent placement. While effective, ticlopidine has serious side effects, unlike clopidogrel.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Aspirin and ticlopidine are effective in preventing post-stent thrombosis.
- Ticlopidine has significant side effects and a slow onset of action.
Purpose of the Study:
- To compare the efficacy and safety of clopidogrel with ticlopidine for preventing stent thrombosis.
- To evaluate clopidogrel as an alternative antiplatelet therapy after stent placement.
Main Methods:
- Review of randomized trials and observational data comparing antiplatelet therapies.
- Analysis of efficacy in preventing thrombosis and ischemic complications.
- Assessment of side effect profiles and onset of action.
Main Results:
- Clopidogrel demonstrates comparable efficacy to ticlopidine in preventing stent thrombosis.
- Clopidogrel offers a superior safety profile with fewer adverse events compared to ticlopidine.
- Clopidogrel provides a faster onset of action, particularly with large loading doses.
Conclusions:
- Clopidogrel is a well-tolerated and effective alternative to ticlopidine for antiplatelet therapy post-stent placement.
- Further research is needed to determine optimal clopidogrel loading doses and therapy duration.